[HTML][HTML] Poly (ADP-ribose) polymerase inhibitors have comparable efficacy with platinum chemotherapy in patients with BRCA-positive metastatic castration-resistant …
Context Testing for mutations in Breast Cancer Gene 1/2 (BRCA) has emerged as a novel
decision-making tool for clinicians. Patients with metastatic castration-resistant prostate …
decision-making tool for clinicians. Patients with metastatic castration-resistant prostate …
Therapeutic sensitivity to standard treatments in BRCA positive metastatic castration-resistant prostate cancer patients—a systematic review and meta-analysis
Background Recent oncology guidelines recommend BRCA1/2 testing for a wide range of
prostate cancer (PCa) patients. In addition, PARP inhibitors are available for mutation …
prostate cancer (PCa) patients. In addition, PARP inhibitors are available for mutation …
Prognostic significance of pathogenic variants in BRCA1, BRCA2, ATM and PALB2 genes in men undergoing hormonal therapy for advanced prostate cancer
H Kimura, K Mizuno, M Shiota, S Narita… - British journal of …, 2022 - nature.com
Background The prognostic significance of germline variants in homologous recombination
repair genes in advanced prostate cancer (PCa), especially with regard to hormonal …
repair genes in advanced prostate cancer (PCa), especially with regard to hormonal …
PARP inhibitors in metastatic prostate cancer: a comprehensive systematic review and meta-analysis of existing evidence
F Ditonno, A Bianchi, S Malandra, AB Porcaro… - Clinical Genitourinary …, 2023 - Elsevier
Background Poly (ADP-ribose) polymerase inhibitors (PARPi) represent an option in
selected cases of metastatic castration-resistant prostate cancer (mCRPC). The aim of the …
selected cases of metastatic castration-resistant prostate cancer (mCRPC). The aim of the …
Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
J Hwang, X Shi, A Elliott, TE Arnoff, J McGrath… - Clinical Cancer …, 2023 - AACR
Purpose: In patients with metastatic prostate cancer (mPC), ATM and BRCA2 mutations
dictate differences in PARPi inhibitor response and other therapies. We interrogated the …
dictate differences in PARPi inhibitor response and other therapies. We interrogated the …
Germline and somatic mutations in prostate cancer: Implications for treatment
C Chalker, B Chun, AO Sokolova - Current problems in cancer, 2024 - Elsevier
Genetic testing is an integral part of the workup of metastatic prostate cancer, in part,
because the results can have a profound impact on the subsequent management of this …
because the results can have a profound impact on the subsequent management of this …
The growing role of rucaparib in contemporary treatment of metastatic prostate cancer: a review of efficacy and guidance for side effect management
A Rao, ES Antonarakis - Expert Review of Anticancer Therapy, 2022 - Taylor & Francis
ABSTRACT Introduction In May 2020, the approval of rucaparib–a poly-ADP-ribose
polymerase (PARP) inhibitor–in the USA marked the arrival of a new class of targeted …
polymerase (PARP) inhibitor–in the USA marked the arrival of a new class of targeted …
Differential responses to taxanes and PARP inhibitors in ATM‐ versus BRCA2‐mutated metastatic castrate‐resistant prostate cancer
CT Su, E Nizialek, JE Berchuck… - The …, 2023 - Wiley Online Library
Background PARP (poly (ADP‐ribose) polymerase) inhibitors (PARPi) are now standard of
care in metastatic castrate‐resistant prostate cancer (mCRPC) patients with select mutations …
care in metastatic castrate‐resistant prostate cancer (mCRPC) patients with select mutations …
Positive response to niraparib in chemo-refractory patients with metastatic appendiceal mucinous adenocarcinoma harboring ATM mutations: A case report
J Wang, H He, W Xu, J Chen - Frontiers in Oncology, 2023 - frontiersin.org
Background Appendiceal mucinous adenocarcinoma, one kind of specific colorectal cancer,
is lowly prevalent and rarely diagnosed in clinical practice. In addition, there have been …
is lowly prevalent and rarely diagnosed in clinical practice. In addition, there have been …
Prevalence of Genetic Mutations in Patients with Metastatic Prostate Cancer in a Cohort of Mexican Patients
OE Rodríguez González, EI Bravo Castro… - Société Internationale d …, 2024 - mdpi.com
Background: Prostate cancer is a malignant neoplasm of the male genitourinary system with
the highest incidence worldwide. Susceptibility genes related to aggressiveness and …
the highest incidence worldwide. Susceptibility genes related to aggressiveness and …